Processa Pharmaceuticals
PCSA
9 hedge funds and large institutions have $251K invested in Processa Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 12 closing their positions.
0.24% more ownership
Funds ownership: 0.01% → 0.25% (+0.24%)
33% less capital invested
Capital invested by funds: $376K → $251K (-$125K)
50% less funds holding
Funds holding: 18 → 9 (-9)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$154K |
| 2 |
Two Sigma Investments
New York
|
+$73.4K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$555 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$106K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$40.8K |
| 3 |
ST
Spinnaker Trust
Portland,
Maine
|
-$25.7K |
| 4 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
-$21.7K |
| 5 |
Renaissance Technologies
New York
|
-$19K |
PCSA Hedge Fund Activity: Q1 2024 in Review
9 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q1 2024, worth a combined $251K — down 33% from $376K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PCSA and 3 opened new positions — a net loss of 9 holders — while 0 trimmed existing stakes and 5 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $154K. The largest seller was Citadel Advisors, exiting entirely with an estimated $106K sold.
- 9 institutional investors held Processa Pharmaceuticals (PCSA) as of Q1 2024, down from 18 in Q4 2023.
- Funds reported $251K of Processa Pharmaceuticals stock for Q1 2024, down 33% quarter-over-quarter.
- 3 funds opened new Processa Pharmaceuticals positions in Q1 2024 and 12 closed out, a net change of -9 holders.
- The largest Processa Pharmaceuticals buyer in Q1 2024 was Sabby Management, an estimated $154K added.
- The largest Processa Pharmaceuticals seller in Q1 2024 was Citadel Advisors, an estimated $106K sold.
Based on aggregated 13F filings for Q1 2024.